Rubitecan
From Infogalactic: the planetary knowledge core
![]() |
|
Systematic (IUPAC) name | |
---|---|
(4S)-4-ethyl-4-hydroxy-11-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
|
|
Clinical data | |
Routes of administration |
Oral |
Identifiers | |
CAS Number | 91421-42-0 ![]() |
ATC code | none |
PubChem | CID: 472335 |
ChemSpider | 414807 ![]() |
UNII | H19C446XXB ![]() |
ChEBI | CHEBI:90225 |
ChEMBL | CHEMBL77305 ![]() |
Synonyms | (19S)-19-ethyl-19-hydroxy-10-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione |
Chemical data | |
Formula | C20H15N3O6 |
Molecular mass | 393.349 g/mol |
|
|
|
|
![]() ![]() |
Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by Supergen.
History
On January 27, 2004, Supergen announced that it has completed the submission of an NDA for rubitecan to the US FDA, [1] and was accepted for filing on March 2004.[2]
On January 2005, Supergen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval,[3] and on January 2006, the Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMA) was also withdrawn.[4]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with reference errors
- Chemical articles having calculated molecular weight overwritten
- Articles with changed InChI identifier
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Topoisomerase inhibitors
- Antineoplastic and immunomodulating drug stubs